This is a demo store. No orders will be fulfilled.

CK2/ERK8-IN-1

    级别和纯度:
  • ≥99%
有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭
货号 (SKU) 包装规格 是否现货 价格 数量
C650431-5mg
5mg 期货 Stock Image
C650431-10mg
10mg 期货 Stock Image
C650431-50mg
50mg 期货 Stock Image
C650431-100mg
100mg 期货 Stock Image

基本描述

别名 CK2/ERK8 合一
英文别名 GTPL8140 | TMCB | CK2/ERK8-IN-1 | Casein Kinase II Inhibitor VI | 2-[4,5,6,7-tetrabromo-2-(dimethylamino)benzimidazol-1-yl]acetic acid | [4,5,6,7-Tetrabromo-2-(Dimethylamino)-1h-Benzimidazol-1-Yl]acetic Acid | 2-(4,5,6,7-Tetrabromo-2-(dimethylamino)-1H-be
规格或纯度 ≥99%
英文名称 CK2/ERK8-IN-1
生化机理 CK2/ERK8-IN-1 是酪蛋白激酶 2(CK2)(K i 为 0.25 µM)和 ERK8(MAPK15、ERK7)的双重抑制剂,IC 50 s 为 0.50 μM。CK2/ERK8-IN-1 还能与 PIM1、HIPK2(同源染色体互作蛋白激酶 2)和 DYRK1A 结合,其 K i s 分别为 8.65 µM、15.25 µM、a.2 µM。
储存温度 -20°C储存
运输条件 超低温冰袋运输
作用类型 激活剂
产品介绍


CK2/ERK8-IN-1 is a dual casein kinase 2 (CK2) ( K i of 0.25 µM) and ERK8 (MAPK15, ERK7) inhibitor with IC 50 s of 0.50 μM. CK2/ERK8-IN-1 also binds to PIM1 , HIPK2 ( homeodomain-interacting protein kinase 2 ), and DYRK1A with K i s of 8.65 µM, 15.25 µM, and 11.9 µM, respectively. CK2/ERK8-IN-1 has pro-apoptotic efficacy

In Vitro

CK2/ERK8-IN-1 (Compound K66; 0-50 µM; 24 hours; Jurkat cells) treatment displays cytotoxic activity in Jurkat cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: Jurkat cells Concentration: 0-50 µM Incubation Time: 24 hours Result: Inhibited cell growth in a dose-dependent manner.

Form:Solid

IC50& Target:CK2 0.5 μM (IC 50 ) CK2 0.25 μM (Ki) ERK8 0.5 μM (IC 50 ) PIM1 8.65 μM (Ki) HIPK2 15.25 μM (Ki) DYRK1A 11.9 μM (Ki) Apoptosis

纯度 ≥99%

关联靶点(人)

CSNK2A2 Tchem 酪蛋白激酶 II 亚基 α'(Casein kinase II subunit alpha') (1 活性数据)
活性类型 活性值-log(M) 作用机制 期刊 参考文献(PubMed IDs)
CSNK2A1 Tchem 酪蛋白激酶 II 亚基 α(Casein kinase II subunit alpha) (0 活性数据)
活性类型 活性值-log(M) 作用机制 期刊 参考文献(PubMed IDs)
CSNK2A1 Tchem Casein kinase II alpha (3512 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
CSNK2A2 Tchem Casein kinase II alpha (prime) (1587 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
LNCaP (8286 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID

作用机制

作用机制 Action Type target ID Target Name Target Type Target Organism Binding Site Name 参考文献

名称和识别符

分子类型 小分子
IIUPAC Name 2-[4,5,6,7-tetrabromo-2-(dimethylamino)benzimidazol-1-yl]acetic acid
INCHI 1S/C11H9Br4N3O2/c1-17(2)11-16-9-7(14)5(12)6(13)8(15)10(9)18(11)3-4(19)20/h3H2,1-2H3,(H,19,20)
InChi Key PHAOTASRLQMKBE-UHFFFAOYSA-N
Smiles CN(C)C1=NC2=C(N1CC(=O)O)C(=C(C(=C2Br)Br)Br)Br
Isomeric SMILES CN(C)C1=NC2=C(N1CC(=O)O)C(=C(C(=C2Br)Br)Br)Br
关联CAS 905105-89-7
PubChem CID 46943415
MeSH Entry Terms (4,5,6,7-tetrabromo-2-(dimethylamino)-1H-benzo(d)imidazol-1-yl)acetic acid;4,5,6,7-tetrabromo-2-(dimethylamino)-1H-benzimidazole-1-acetic acid
分子量 534.82

化学和物理性质

溶解性 DMSO : 16.67 mg/mL (31.17 mM; Need ultrasonic)
分子量 534.820 g/mol
XLogP3 4.400
氢键供体数Hydrogen Bond Donor Count 1
氢键受体数Hydrogen Bond Acceptor Count 4
可旋转键计数Rotatable Bond Count 3
精确质量Exact Mass 534.739 Da
单同位素质量Monoisotopic Mass 530.743 Da
拓扑极表面积Topological Polar Surface Area 58.400 Ų
重原子数Heavy Atom Count 20
形式电荷Formal Charge 0
复杂度Complexity 387.000
同位素原子数Isotope Atom Count 0
定义的原子立体中心计数Defined Atom Stereocenter Count 0
未定义的原子立体中心计数Undefined Atom Stereocenter Count 0
定义的键立体中心计数Defined Bond Stereocenter Count 0
未定义的键立体中心计数Undefined Bond Stereocenter Count 0
所有立体化学键的总数The total count of all stereochemical bonds 0
共价键合单元计数Covalently-Bonded Unit Count 1

质检证书(CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:

溶液计算器